Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort.

Abstract

Recurrent hepatitis C is a major cause of mortality in HIV/hepatitis C virus (HCV)-co-infected patients after orthotopic liver transplantation. We report sustained viral clearance in all four transplanted HIV/HCV-positive patients treated with pegylated interferon/ribavirin. Early therapy after HCV recurrence, tailoring treatment duration to the individual decline in HCV-RNA and the management of side effects are key factors for improved efficacy. At experienced centres interferon treatment is a valuable option for recurrent hepatitis C in HIV-positive patients.

• Authors: Kamila Wojcik, Martin Vogel, Esther Voigt, Nicola Speidel, Jörg C Kalff, Georg Goldmann, Johannes Oldenburg, Tilman Sauerbruch, Jürgen Kurt Rockstroh, Ulrich Spengler
• Journal: AIDS (London, England) (AIDS) Vol. 21 Issue 10 Pg. 1363-5 (Jun 19 2007) ISSN: 0269-9370 [Print] England
• PMID: 17545715 (Publication Type: Journal Article)

Chemical References

• Antiviral Agents
• Interferon alpha-2
• Interferon-alpha
• RNA, Viral
• Recombinant Proteins
• Polyethylene Glycols
• Ribavirin
• peginterferon alfa-2a

Topics

• Administration, Oral
• Antiviral Agents (administration & dosage)
• Cohort Studies
• Drug Therapy, Combination
• HIV Infections (complications, drug therapy)
• Hepatitis C (complications, drug therapy)
• Hepatitis C, Chronic (complications, surgery)
• Humans
• Injections, Subcutaneous
• Interferon alpha-2
• Interferon-alpha (administration & dosage)
• Liver Transplantation
• Polyethylene Glycols (administration & dosage)
• RNA, Viral (analysis)
• Recombinant Proteins
• Recurrence
• Ribavirin (administration & dosage)
• Treatment Outcome